ANDA 204552, held by Chartwell Molecular. Aspirin; Dipyridamole.
As of Nov 22, 2026, ANDA 204552 (Aspirin and Dipyridamole), held by Chartwell Molecular, was first approved by FDA on Mar 20, 2019, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aspirin and Dipyridamole25MG;200MG · capsule, extended release;oral | Aspirin; Dipyridamole | Discontinued |
| Aug 29, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 29, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 20, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters